Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 272

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy

Krishnan, Sunil, Rana, Vishal, Janjan, Nora A., Varadhachary, Gauri R., Abbruzzese, James L., Das, Prajnan, Delclos, Marc E., Gould, Morris S., Evans, Douglas B., Wolff, Robert A., Crane, Christopher H.·2007·Cancer

Abstract

BACKGROUND.: The current study was conducted to determine whether there were differences in outcome for patients with unresectable locally advanced pancreatic cancer (LAPC) who received treatment with chemoradiation therapy (CR) versus induction chemotherapy followed by CR (CCR). METHODS.: Between December 1993 and July 2005, 323 consecutive patients with LAPC were treated at the authors' institution with radiotherapy and concurrent gemcitabine or fluoropyrimidine chemotherapy. Two hundred forty‐seven patients received CR as initial treatment, and 76 patients received a median of 2.5 months of gemcitabine‐based induction chemotherapy prior to CR. Most patients received a radiation dose of 30 grays in 10 fractions (85%) concurrently with infusional 5‐fluorouracil (41%), gemcitabine (39%), or capecitabine (20%). RESULTS.: The median follow‐up was 5.5 months (range, 1–63 months). For all patients, the median overall survival (OS) and progression‐free survival (PFS) were 9 months and 5 months, respectively, and the 2‐year estimated OS and PFS rates were 9% and 5%, respectively. The median OS and PFS were 8.5 months and 4.2 months, respectively, in the CR group and 11.9 months and 6.4 months, respectively, in the CCR group (both P < .001). The median times to local and distant progression were 6.0 months and 5.6 months, respectively, in the CR group and 8.9 and 9.5 months, respectively, in the CCR group (P = .003 and P = .007, respectively). There was no significant difference in the patterns of failure with the use of induction chemotherapy. CONCLUSIONS.: The results from this analysis indicated that, by excluding patients with rapid distant progression, induction chemotherapy may select patients with LAPC for optimal benefit from consolidative CR. The authors believe that this strategy of enriching the population of patients who receive a locoregional treatment modality merits prospective randomized evaluation. Cancer 2007. © 2007 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.22735

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 272

Metadata

Authors
Krishnan, S., Rana, V., Janjan, N. A., Varadhachary, G. R., Abbruzzese, J. L., Das, P., Delclos, M. E., Gould, M. S., Evans, D. B., Wolff, R. A., & Crane, C. H.
Venue
Cancer
Publisher
Wiley
Published
2007-06-15
Volume
110
Issue
1
Pages
47-55
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2029845350
Cited by
272
References
18
FWCI
6.94
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. https://app.cochat.ai/papers/10.1002/cncr.22735
The paper
Krishnan, S., Rana, V., Janjan, N. A., Varadhachary, G. R., Abbruzzese, J. L., Das, P., Delclos, M. E., Gould, M. S., Evans, D. B., Wolff, R. A., & Crane, C. H. (2007). Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer. https://doi.org/10.1002/cncr.22735

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.